RxDoctor Payments Data

John Lee, MD

Family Medicine · New Braunfels, TXNPI 1255367108

Payments from drug & device makers

$7,603in general payments, 2019–2025

Across 407 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$924
  • Lilly USA, LLC$886
  • GSK$684
  • Amarin Pharma, Inc.$547
  • AstraZeneca$392
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,597100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,603 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$209,305
Medicare patients
326
Services billed
2,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$127,476
FarxigaDapagliflozin Propanediol113$127,123
JardianceEmpagliflozin100$104,502
MounjaroTirzepatide63$77,986
EliquisApixaban63$63,561
TrulicityDulaglutide51$60,462
RybelsusSemaglutide30$55,132
Synjardy XrEmpagliflozin/Metformin Hcl41$42,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$39,992
ProliaDenosumab13$21,304
VascepaIcosapent Ethyl30$18,488
JanuviaSitagliptin Phosphate15$17,959
MyrbetriqMirabegron23$14,984
Xigduo XrDapaglifloz Propaned/Metformin11$9,305
Levothyroxine Sodium365$6,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$924$182,608141 claims
Boehringer IngelheimJardiance, Synjardy Xr$361$147,247141 claims
Lilly USA, LLCMounjaro, Trulicity$886$138,448114 claims
AstraZenecaFarxiga$392$127,123113 claims
PfizerEliquis$282$63,56163 claims
GSKTrelegy Ellipta$684$39,99226 claims
AmgenProlia$308$21,30413 claims
MerckJanuvia$129$17,95915 claims
Astellas Pharma US IncMyrbetriq$94$14,98423 claims
Johnson & JohnsonXarelto$141$6,51311 claims
AbbVieSynthroid$1,030$2,35740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →